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Abstract Anomalous choline metabolic patterns have
been consistently observed in vivo using Magnetic Reso-
nance Spectroscopy (MRS) analysis of patients with
neurodegenerative diseases and tissues from cancer patient.
It remains unclear; however, what signaling events may
have triggered these choline metabolic aberrancies. This
study investigates how changes in choline and phospholipid
metabolism are regulated by distinct changes in the mito-
chondrial electron transport system (ETS). We used speciﬁc
inhibitors to down regulate the function of individual pro-
tein complexes in the ETS of SH-SY5Y neuroblastoma
cells. Interestingly, we found that dramatic elevation in the
levels of phosphatidylcholine metabolites could be induced
by the inhibition of individual ETS complexes, similar to
in vivo observations. Such interferences produced diver-
gent metabolic patterns, which were distinguishable via
principal component analysis of the cellular metabolomes.
Functional impairments in ETS components have been
reported in several central nervous system (CNS) diseases,
including Alzheimer’s disease (AD) and Parkinson’s dis-
ease (PD); however, it remains largely unknown how the
suppression of individual ETS complex function could lead
to speciﬁc dysfunction in different cell types, resulting in
distinct disease phenotypes. Our results suggest that the
inhibition of each of the ﬁve ETS complexes might differ-
entially regulate phospholipase activities within choline
metabolic pathways in neuronal cells, which could con-
tribute to the overall understanding of mitochondrial
diseases.
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1 Introduction
Choline (Cho) and related lipid metabolites are vital for
manyaspectsofcellularstructureandfunction.Inadditionto
being an important precursor for the synthesis of acetyl-
choline, a neurotransmitter, it is also required for the
synthesis of phosphatidylcholine, sphingosylphosphorylch-
oline and other phospholipids, which are important for
maintaining cell membrane integrity and facilitating signal
transduction. Furthermore, Cho is an important methyl-
group donor for the synthesis of S-adenosine methionine, an
essential metabolite for the methylation of DNA and protein
molecules. It is now clear that the deregulation of Cho
metabolic pathways has a profound effect on cellular phys-
iology. Abnormal Cho metabolism has been reported in
several diseases where mitochondrial dysfunction is impli-
cated (Farber et al. 2000; Michel et al. 2006). In many cases
such alterations are characterized by an increase in the
amount of total choline metabolite (tCho), which is
increasingly utilized as one of the biomarkers for mito-
chondrial dysfunction (Jenkins et al. 2005; Meyerhoff et al.
1994). For instance, brain cells in AD show membrane
defects associated with increased phospholipid turnover,
which is characterized by a decrease in Cho and phospho-
rylcholine(PC)andanincreaseinglycerophosphorylcholine
(GPC) and cytidine diphosphate choline (CDP-Cho) (Farber
et al. 2000).
The exact relationship between Cho metabolism and
mitochondrial dysfunction has not been well understood,
but there is increasing evidence that they are functionally
connected. Clinical studies using MRS have reported ele-
vations in both tCho and PC in numerous human solid
tumors (Negendank 1992; Podo 1999) and in animal
models including breast, ovarian (Aboagye and Bhujwalla
1999) and brain tumors (Barker et al. 1993). Mitochondrial
functional adaptation to hypoxia has been well documented
in various cancer models (Glunde et al. 2006). Recently,
hypoxia inducible factor-1a (HIF-1a) was shown to induce
choline kinase, a key enzyme responsible for the synthesis
of PC from Cho in metastatic cancer cells (Glunde et al.
2008). In addition to cancer, MRS studies have also
reported changes in Cho metabolites in several CNS dis-
eases associated with mitochondrial abnormalities. Higher
tCho/creatine ratios were reported in the posterior mesial
gray matter in AD versus control patients (MacKay et al.
1996). Similarly, a signiﬁcant increase in tCho metabolites
was also observed in basal ganglia (Clarke and Lowry
2000). Furthermore, tCho metabolites were found to be
increased in a rodent model of Huntington’s disease (HD)
(Jenkins et al. 1993). In order to understand the func-
tional signiﬁcance of Cho metabolism in mitochondrial
dysfunction, we embarked on a metabolomics study of
SH-SY5Y neuroblastoma cells treated with speciﬁc mito-
chondrial ETS complex inhibitors. This work stems from
the fact that complex-speciﬁc ETS inhibitors have been
shown to induce symptoms in animal models resembling
those observed in different human CNS diseases (Brouillet
et al. 1999; Kanthasamy et al. 1994; Tetrud and Langston
1989). For example, Complex I inhibition within dopami-
nergic neurons has been associated with the development
of PD (Schmidt and Ferger 2001; Sherer et al. 2002); while
a decrease in Complexes II/III activities have been seen in
select populations of HD patients (Beal 1998). In addition,
Complex IV defects have been observed in animal models
of AD (Ohta and Ohsawa 2006).
We report here that inhibition of mitochondrial ETS
complexes alters Cho catabolic and anabolic pathways,
producing NMR spectral patterns similar to those observed
by MRS in vivo. In addition, distinct metabolomic patterns
following inhibition of individual ETS complexes can be
differentiated using
1H-NMR analysis of cellular metabo-
lites. In particular, we found that the relative levels of three
Cho metabolites, Cho, PC and GPC, were among the most
dramatically affected cellular metabolites by the inhibition
of individual ETS complex. Differential induction of a
choline-metabolizing lipase, choline kinase, has been
detected following the inhibition of speciﬁc ETS com-
plexes. Finally, we discuss a possible relationship between
Cho turnover and mitochondrial dysfunction via phospho-
lipase modulation.
2 Materials and methods
2.1 Materials
A human neuroblastoma SH-SY5Y cell line was obtained
from American Type Culture Collection (MD, USA).
Dulbecco’s modiﬁed Eagle’s medium (DMEM), trypsin-
MEM (0.05%) and penicillin/streptomycin were purchased
from Mediatech Inc. (VA, USA). Glucose-free DMEM and
phosphate-buffered saline (PBS) were obtained from Gibco
(Grand Island, NY). Fetal bovine serum (FBS) was
obtained from TC Biologicals (Tulare, CA) Deuterium
oxide (D2O, 99.996%), 3-(trimethylsilyl)propionic-2,2,3,3-
d4 acid (TSP), deuterium chloride (DCl, 99% D), sodium
deutoroxide (NaOD, 99.5% D), 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), 3-nitropropionic acid (3-NP),
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123oligomycin, antimycin-A, sodium azide, ferulic acid, cho-
line chloride, acetylcholine and phosphorylcholine chloride
were purchased from Sigma-Aldrich (St. Louis, MS).
Perchloric acid (70–72%) was purchased from JT Baker
(Phillipsburg, NJ).
2.2 Cell culture and ETS inhibition
SH-SY5Ycellswereseededinpoly-D-lysinecoated150 cm
2
polystyrene culture dishes and grown in DMEM containing
10% FBS, penicillin (100 units/ml), streptomycin (100 lg/
ml) and non-essential amino acids (NAA) and incubated at
37Cinahumidiﬁedatmosphereof5%CO2and95%air.For
eachmetabolicreactionanalysis,8 9 10
7 cellswereused.It
was expected that the interferences of the ETS Complexes I
to V by increasing concentrations of complex speciﬁc
inhibitors would decrease cellular metabolism, promote
reactive oxygen species production and eventually lead to
cell death, therefore, at the inhibitor concentrations chosen
for this study, we aimed to achieve approximately 80% cell
viability after each treatment. This biological response-
basednormalizationundertookconsiderationsofdifferential
inhibitor transport, metabolism and inhibition kinetics,
allowing the distinction of cellular metabolomes and the
comparison of complex-speciﬁc metabolomic patterns.
Once 80–90% conﬂuence was reached, cells were incubated
with fresh DMEM containing 10% FBS, penicillin
(100 units/ml),streptomycin(100 lg/ml)andNAAplusone
of the following ETS inhibitors: 1 mM MPTP, 5 mM 3-NP,
4 lg/ml antimycin-A, 2 mM sodium azide or 1 lg/ml oli-
gomycin. All ETS inhibition reactions were carried out for
24 h, except 3-NP, which was for only 12 h. Cells were
counted after each ETS inhibition and overall cell viability
was maintained at around 80%. A control cell culture was
included along with each ETS inhibition reaction. All
experiments were carried out in triplicate for NMR and with
ﬁve repetitions for mass spectrometry (MS).
2.3
1H-NMR spectroscopy
After the incubation, the culture medium was removed and
the cells were washed twice with ice-cold PBS and frozen
immediately. Cells were scraped from the culture dishes
and the metabolites were extracted with ice-cold perchloric
acid (12%) and neutralized with 5 M KOH. The suspension
was centrifuged at 15,000 9 g to remove the insoluble
KClO4 formed and the remaining cell debris and super-
natants were stored at -80C following lyophilization.
Prior to NMR analysis, the samples were dissolved in
300 llo fD 2O and pD was adjusted to 7.0–7.3 with DCl
and NaOD.
1H-NMR spectra were recorded on an
800 MHz Bruker Avance spectrometer (Nuclear Magnetic
Resonance Core Facility, RPI, Troy, NY) with a 5-mm
ultra sensitive HCN inverse triple resonance cryoprobe.
Each spectrum was acquired over 256 scans, and water
suppression was achieved by a presaturation pulse
sequence, based on the start of the NOESY pulse sequence
at 25C. Each spectrum was recorded with 10 s repetition
time, 8,621 Hz spectral width and 32 K data size. Chemi-
cal shifts were referenced to the methyl protons of lactate
at 1.32 ppm.
2.4 Quantiﬁcation of metabolites by NMR
The relative amounts of cellular metabolites were calcu-
lated from the fully relaxed
1H-NMR spectra of the cell
extracts using (trimethylsilyl)propionic-2,2,3,3,d4-acid
(TSP) as the external standard. Chemical shift assignments
were conﬁrmed both by performing additional 2D NMR
experiments and by comparison with the reported chemical
shifts and coupling constants of the metabolites (Gov-
indaraju et al. 2000).
1H-NMR spectra were phased and
baseline corrected, then integrated between 0.5 and
4.5 ppm and binned into 0.04 ppm integral regions with
MestrecC (MESTRELAB RESEARCH SL, Santiago de
Compostela, Spain). Individual integral regions were nor-
malized to the total spectra excluding the water region, so
each bin was normalized to the total metabolite concen-
tration in each sample. The data were then transferred to
the SIMCA package (Umetrics, Umea, Sweden) and pre-
processed using pareto-scaling. This processing procedure
weighs each integral region by (1/Sk)1/2, where Sk repre-
sents the standard deviation of the variables and increases
the representation of lower concentration metabolites while
minimizing the noise (Pears et al. 2005). Statistical anal-
ysis of individual metabolites among the ETS inhibition
group means was calculated using an unpaired two-tailed
student’s t-test using Microsoft Excel, with P B 0.05
considered signiﬁcant. The relative changes are presented
as mean ± SD.
2.5 Principal component analysis (PCA)
SIMCA package was used to simplify NMR spectral data
comparison and to identify the differences among sets of
NMR data (n = 3 for each treatment, total 6 groups). The
unsupervised method was used to analyze the data. Two
types of plots are usually generated with this method. The
score plot shows the similarities and differences among the
data sets. The data sets exhibiting similarities are clustered
together and those that are different are placed further
apart; therefore, one can quickly judge the degree of sim-
ilarity among the data sets. The second plot is called a
loadings plot and shows the variables/buckets responsible
for the variation within the dataset. This plot helps to
pinpoint the exact metabolites or NMR spectral features
Metabolomics of ETS inhibition 349
123that are the differentiating factors for the separation of
clusters. The PCA score values were subjected to ANOVA
in order to evaluate the statistical differences among
sample groups.
2.6 Mass spectrometry and quantiﬁcation
of Cho and PC
Subsequent to treating the SH-SY5Y neuroblastoma cells
with each of the ﬁve ETS inhibitors, the metabolites were
extracted with 250 ll of ice-cold perchloric acid (12%).
The supernatants were neutralized with 250 ll of 1.5 M
KOH and centrifuged at 14,000 rpm to remove insoluble
materials. Metabolite analysis was performed on an Applied
Biosystems Inc. 4800 Proteomics Analyzer matrix-assisted
laser desorption/ionization mass spectrometer (MALDI-
TOF MS), where MS spectra (m/z 50–300) were acquired in
positive ion and reﬂectron mode with external mass cali-
bration. Each spectrum was averaged over 2200 laser shots.
The matrix solution composition was 10 mg/ml ferulic acid
in 30% acetonitrile plus 0.1% triﬂuoroacetic acid. One ml of
matrix was spiked with 200 pmol of acetylcholine as the
internal standard for quantiﬁcation. Two micro liters from
each sample was mixed with an equal volume of the matrix
solution and four aliquots of 0.5 ll each were spotted onto
an Opti-TOF MALDI target plate. In order to compensate
for analytical and biological variation, Cho (m/z 104.1) and
PC (m/z 184.1) ion counts were ﬁrst divided by the ace-
tylcholine ion signals. The metabolites were then
normalized against the total metabolite ion counts. Each
treatment group had ﬁve repetitions. The relative changes
are presented as mean ± SD relative to the controls.
Microsoft Excel was used to calculate the P values using
unpaired two-tailed student’s t-tests.
2.7 Western blot
After the treatments, cells were washed with ice-cold PBS
and lysed in lysis buffer (20 mM Tris, 150 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1% Triton X 100) plus pro-
tease inhibitors (Sigma, St. Louis, USA). Twenty
micrograms of proteins from each sample was resolved
over a 12% SDS-PAGE gel and transferred to a nitrocel-
lulose membrane (Millipore, USA). The membrane was
ﬁrst blocked in the blocking buffer (5% nonfat dry milk,
0.1% Tween 20; in PBS) for 1 h at room temperature and
then incubated with an antibody against choline kinase
(ab38290, Abcam, Cambridge, USA) in blocking buffer for
overnight at 4C. After washing, the membrane was incu-
bated with an HRP-conjugated goat anti-rabbit secondary
antibody (Bio-Rad, Hercules, USA) for 1 h at room tem-
perature and detected by chemiluminescence. Equal
protein loading was conﬁrmed by stripping the blot and
re-probing with a b-actin antibody (Santa Cruz Biotech-
nology, Santa Cruz, USA).
3 Results
3.1
1H-NMR analysis of SH-SY5Y cell metabolome
Metabolites derived from SH-SY5Y cells treated with each
inhibitor were extracted with perchloric acid and analyzed
by
1H NMR. An
1H-NMR spectrum of a control sample is
shown in Fig. 1a. The high-resolution 800 MHz
1H-NMR
spectra enabled us to assign the spectral signals to various
metabolites with high conﬁdence (Govindaraju et al.
2000). Fifteen known metabolites were quantiﬁed after
manual phasing and baseline corrections for deviations
(Table 1).
3.2 Distinct changes in choline metabolites
Inhibition of speciﬁc ETS complexes resulted in the dis-
tinct changes in several Cho metabolites (Fig. 1). Because
there were only three replicates for the NMR analysis as a
result of long data acquisition time required on the NMR,
changes in Cho and PC could not be conﬁdently deter-
mined for several treatments. Therefore, we also analyzed
Cho and PC by MS as a complimentary analysis, to
improve statistical signiﬁcance of the measurements
(Fig. 1d, e; Supplemental Table 1). Although all ﬁve of the
ETS complex inhibitors showed signiﬁcant increases in
GPC levels (Fig. 1c), only 3-NP, antimycin-A and azide
treatments produced elevated free Cho (Fig. 1e). In con-
trast, MPTP treatment resulted in decrease of free Cho,
(Table 1, Fig. 1c, e). PC levels were elevated by MPTP
and azide treatments, respectively (Table 1, Fig. 1c). On
the other hand, 3-NP, antimycin-A and oligomycin treat-
ments caused a decrease in PC (Fig. 1e).
3.3 Distinct metabolomic patterns following ETS
inhibition
Treatments of SH-SY5Y neuroblastoma cells with MPTP,
3-NP, antimycin-A, azide or oligomycin resulted in the
inhibition of mitochondrial ETS Complexes I through V,
respectively. This inhibition created perturbations in a
number of metabolites.
1H-NMR spectra was divided into
0.04 ppm buckets and PCA analysis was applied for all the
treatments. Patterns from PCA analysis of the chemical
shift intensity information within all NMR spectra revealed
that different inhibitors showed clear separations among
one another and with the control cells (Fig. 2), meaning
that the
1H-NMR spectral signatures of each ETS complex
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123inhibition group were distinguishable. The clustering of
each sample group is depicted with the PCA score plot
(Fig. 2a), where each treated cell group produced signiﬁ-
cantly distinct NMR patterns, resulting in spatial
separations among the treatment groups in the plot. On the
other hand, some metabolic similarities and PCA over-
lapping were seen for antimycin-A and azide-treated cells
(Complexes III and IV inhibition). Studying the principal
component 1 and 2 loading plots and the respective spectra
showed that the primary differentiating buckets belonged
to Cho metabolites, including free Cho (3.20 ppm), PC
(3.22 ppm) and GPC (3.24 ppm) (Fig. 2b, c). In addition,
some alterations in glutamate, glutamine and branched
chain amino acids were also observed (Fig. 2b, c).
3.4 Induction of choline kinase by ETS inhibition
In order to establish the causal relationship between ETS
complex inhibition and the observed alterations of choline
metabolites, we performed a western blot analysis of
choline kinase following ETS complex inhibition. Other
than azide inhibition of Complex IV, choline kinase was
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Fig. 1 Changes in choline metabolite levels following ETS complex
inhibition. (a)A n
1H-NMR spectrum of SH-SY5Y neuroblastoma cell
metabolites in the absence of ETS inhibition. Metabolites were
extracted with 12% perchloric acid. BCAA’s: branched chain amino
acids; Lac: lactate; Ala: Alanine; Glu: Glutamate; Gln: Glutamine;
Asp: Aspartate; Cr: Creatine; Cho: Choline; PC: Phosphorylcholine;
GPC: Glycerophosphorylcholine; Tau: Taurine; m-Ino: Myo-inositol;
Gly: Glycine. The chemical shifts were assigned according to
Govindaraju et al. (2000). (b) Select regions within representative
1H NMR spectra where Cho, PC and GPC were detected. Values are
given as % over control, mean ± SD (n = 3, *P\0.05, **P\0.01,
***P\0.001). All ETS complex inhibitors resulted in a combined
increase in total choline metabolites (tCho). (c) Quantitative analysis
of NMR spectral changes in speciﬁc choline metabolites following
each ETS complex inhibitor treatment. (d) A MS spectrum (m/z 50–
300) of a control sample. The masses for Cho and PC are
monoisotopic. (e) Quantitative analysis of Cho and PC by MALDI-
TOF MS. Values are given as % over control, mean ± SD (n = 5,
*P\0.05, **P\0.01, ***P\0.001)
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123substantially induced by all of the ETS inhibitors, albeit to
different degrees (Fig. 3).
4 Discussion
Cho is an essential precursor for the synthesis of phos-
phatidylcholine (PtdCho), an integral component of cell
membranes. It is derived either from diet or from the
catabolism of PtdCho and acetylcholine (Li and Vance
2008). Within normal cells, over 95% of Cho is present as
PtdCho, with 5% as Cho, PC, GPC and other metabolites
(Zeisel and Blusztajn 1994). Although Cho metabolism is
known to occur both at the membrane and the cytosol,
changes in Cho metabolite levels have been suggested to
indicate differential turnover of cellular membranes (Fa-
rooqui et al. 2000), including mitochondrial membranes.
In this study, we used high resolution 800 MHz
1H-NMR
to ascertain whether inhibition of individual ETS com-
plexes in SH-SY5Y neuroblastoma cells could induce the
abnormal Cho metabolic patterns that are reported in
clinical studies of CNS diseases. Indeed, careful exami-
nation of the NMR spectra revealed a dramatic overall
increase in tCho, (Fig. 1b, all three peaks combined) fol-
lowing inhibition of each of the ﬁve ETS complexes
compared with control. There were also clear Cho meta-
bolic differences, however, among the ﬁve different
inhibitors (Fig. 1c, e). To the best of our knowledge, this
is the ﬁrst time that differential choline metabolic patterns
have been directly linked to ETS complex inhibition.
PtdCho and Cho metabolism involves a network of met-
abolic enzymes (Fig. 4). The mechanisms governing how
the inhibition of each ETS complex might regulate
different Cho metabolic enzymes, however, are presently
unknown. Earlier studies have provided some clues that
either the activation of mitochondrial uncoupler (Farber
et al. 2000) or hypoxia (Glunde et al. 2008) is able to
selectively modulate Cho metabolic enzymes and produce
Cho metabolic proﬁles similar to those observed in AD
patients or in cancer cells. Although it is not well docu-
mented that ETS inhibition directly regulate the
metabolism of phospholipids in general or of PtdCho in
particular, it is plausible that inhibition of speciﬁc ETS
complexes could differentially activate selective phos-
pholipid metabolic pathways. Consequently, the resulting
metabolites could serve as indicators for dysfunction of
individual ETS complexes. More importantly, these bio-
active compounds might be responsible for instigating the
signaling events that lead to the manifestation of ETS
complex-speciﬁc mitochondrial dysfunction.
Phospholipids are essential components of the plasma
membrane and the membranes of cellular organelles. In
addition to their structural roles, metabolites derived from
phospholipids can also be important signaling molecules,
regulating a wide range of cellular functions from apop-
tosis to stress response. Among the many signaling
molecules that can be derived from PtdCho, one of the
most abundant phospholipids in eukaryotic membranes, are
lyso-PtdCho, lysophosphatidic acid, phosphatidic acid,
diacylglycerol and arachidonic acid (AA), a precursor to
eicosanoids and endocannabinoids (van Meer et al. 2008).
The production of these signaling molecules is regulated in
a localized fashion by different classes of phospholipases,
including A1,A 2, C and D, based on the speciﬁc bonds
hydrolyzed within the phospholipids. Among the most
widely studied is phospholipase A2 (PLA2), a group of
Table 1 Relative changes of
each metabolite following ETS
complex inhibitions
The percentage ratios were
calculated by dividing the
integration of the respective
peak areas in
1H-NMR spectra
against the values obtained from
the controls. The relative
changes are given as
means ± SD (n = 3,
* P\0.05, ** P\0.01,
*** P\0.001)
ETS complex I II III IV V
Inhibitor MPTP 3-NP Antimycin-A Azide Oligomycin
Val 74.1 ± 6.1** 77.0 ± 7.0** 80.7 ± 6.5** 74.9 ± 0.5*** 78.1 ± 7.3**
Leu 58.2 ± 6.4*** 65.8 ± 4.8*** 66.2 ± 3.9*** 61.1 ± 2.5*** 60.4 ± 7.9**
Ile 65.7 ± 11.3* 80.6 ± 7.8 74.9 ± 7.6* 70.5 ± 2.4** 67.4 ± 10.6*
Lac 91.6 ± 10.2 68.4 ± 4.4** 107.9 ± 4.8 81.0 ± 6.5* 90.1 ± 4.7
Ala 40.4 ± 5.3* 42.6 ± 2.3* 27.4 ± 2.9* 30.2 ± 6.3* 31.2 ± 5.7*
Glu 95.9 ± 10.2 88.3 ± 14.8 100.0 ± 7.9 77.6 ± 5.3 88.4 ± 11.8
Gln 81.7 ± 8.0* 84.0 ± 1.9** 101.7 ± 4.3 64.4 ± 8.3** 82.8 ± 7.2*
Cr, PCr 65.8 ± 1.1** 60.1 ± 4.2** 87.7 ± 8.7 42.4 ± 5.9*** 69.6 ± 11.8*
Cho 46.8 ± 22.7* 171.5 ± 81.9 78.9 ± 19.9 156.9 ± 33.3 22.2 ± 0.8**
PC 187.0 ± 2.5*** 76.6 ± 28.6 115.2 ± 11.6 128.0 ± 9.9* 86.8 ± 5.1
GPC 170.4 ± 19.4** 185.2 ± 20.5** 188.4 ± 29.0** 195.0 ± 25.1** 153.5 ± 23.8*
Tau 70.3 ± 4.7*** 54.6 ± 12.8** 118.2 ± 15.4 58.3 ± 5.2*** 92.5 ± 5.6
m-Ins 113.0 ± 23.5 136.2 ± 27.5 138.1 ± 1.2** 95.7 ± 7.1 126.2 ± 3.6*
Gly 90.8 ± 1.4* 129.4 ± 12.3* 137.3 ± 14.0* 104.7 ± 8.7 85.5 ± 4.9*
Asp 245.5 ± 31.9** 163.8 ± 113.0 237.9 ± 14.8*** 228.6 ± 36.7** 235.7 ± 46.0*
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123enzymes that catalyzes the hydrolysis the sn-2 acyl bond of
phospholipids and can yield AA and lysophospholipids.
The released AA can then be converted by cyclooxygen-
ases into eicosanoids, which are crucial proinﬂammatory
molecules. There are over 20 different isoforms of PLA2,
including cytosolic, Ca
?2-dependent, Ca
?2-independent,
secretory and mitochondrial isoforms. Each is uniquely
regulated and can participate in many different signaling
pathways. Membrane localization and functional activation
of PLA2, for example, is modulated by elevated cellular
calcium concentration and by mitogen-activated protein
kinase (MAPK) phosphorylation. Regulation of mito-
chondrial function by PLA2 variants has been well
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Fig. 2 Principal component analysis of the metabolomes following
all six treatments. (a) A PCA score plot distinguishes the metabolic
proﬁles of SH-SY5Y neuroblastoma cells treated with: I: 1 mM
MPTP; II: 5 mM 3-NP; III: 4 lg/ml antimycin-A; IV: 2 mM sodium
azide and V: 1 lg/ml oligomycin. C: Control cells treated with saline
only. The solid ellipse denotes the 95% signiﬁcance limit (Hotelling
T
2) and the dotted ellipse indicates the differentially inhibited sample
groups (the dotted lines do not have statistical signiﬁcance). (b)
Loading plot for principal component 1 (PC1). (c) Loading plot for
principal component 2 (PC2). The PC1 calculated by this method
represents the largest variation among the data sets and the
subsequent PCs represent lesser variations by comparison. Usually,
the ﬁrst three PCs should be able to explain 50–80% of the total
variation. The resulting PCA scores were subjected to one-way
analysis of variance (ANOVA) in order to test the level of statistical
difference among the sample groups. Differences were considered
signiﬁcant when P B 0.05
Fig. 3 Western blot analysis of choline kinase following ETS
Complex inhibition. Twenty micrograms of proteins derived from
SH-SY5Y cells treated with each of ﬁve ETS complex inhibitors were
loaded on a 12% SDS-PAGE gel and probed with a anti-choline
kinase antibody (ab38290, Abcam) . The results suggest that other
than azide, choline kinase was induced by all of the other inhibitors of
ETS complexes, albeit to a varying degrees compared to untreated
SH-SY5Y cells
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123documented. Recently, Zhu et al. demonstrated that PLA2
was capable of mediating amyloid-b peptide-induced
mitochondrial swelling in astrocytes (Zhu et al. 2006).
Interestingly, Sharpley et al. reported that the activity of
NADH:ubiquinone oxireductase of ETS Complex I was
enhanced by direct interaction with PtdCho (Sharpley et al.
2006), suggesting that PtdCho catabolism could be asso-
ciated with Complex I inhibition. On the other hand, how
ETS inhibition might modulate PLA2 is not well under-
stood. Inhibition of ETS complexes has been shown to
cause elevations of reactive oxygen species (ROS), which
may in turn activate PLA2 via MAPK pathways. We
observed a signiﬁcant increase in GPC from 50% to 100%
with all ﬁve ETS inhibitors, suggesting that accelerated
membrane catabolism could have occurred as a results of
ETS complex inhibition (Podo 1999). Indeed, elevated
GPC has been reported as an indication for increased
phospholipid turnover and membrane defects observed in
AD patients (Farber et al. 2000). Since, we observed
overall elevation of GPC, the end product of combined
activities of PLA1, PLA2 and lysophospholipase, with all
ﬁve ETS complex inhibitors (Fig. 4), these lipases may be
activated by reduced mitochondrial ATP synthesis or ele-
vated ROS. ROS elevation associated with ETS
dysfunction might also compromise membrane integrity;
consequently, Ca
2? level could increase, which in turn
would activate PLA2 and other lipases. Activation of PLA2
in mitochondria has been shown to play a role in phos-
pholipid repair and the reduction of lipid peroxidation and
mitochondrial swelling (Kinsey et al. 2007).
In addition to GPC, Cho and PC are the two metabolites
to be most varied among ETS complex inhibitors (Fig. 1c,
e). This suggests that additional Cho metabolic pathway
enzymes, including phospholipases C and D, choline
kinase and GPC phosphodiesterase (GPC-PDE) might also
be differently affected by the ﬁve ETS inhibitors (Figs. 3,
4), resulting in metabolic proﬁles speciﬁc to the ETS
complex inhibited. Although phospholipase C (PLC) is
usually associated with the release of phosphoinositols
from phosphatidylinositol, a choline-speciﬁc PLC has been
reported (Wolf and Gross 1985). From PtdCho, PLC can
produce PC directly, while phospholipase D (PLD) gen-
erates Cho (Fig. 4). In addition, Cho can be phosphorylated
by choline kinase to synthesize PC. We found that the
elevation of PC following MPTP treatment could be the
result of choline kinase (Fig. 3) and/or choline-speciﬁc
PLC activation. On the other hand, the speciﬁc decrease of
Cho as seen following MPTP treatment could be due to the
inactivation of PLD and/or GPC-PDE, along with the
activation of choline kinase. PLD is broadly expressed in
many eukaryotic cell types and generates Cho and phos-
phatidic acid from PtdCho. A wide range of signals,
including ROS and calcium has been shown to cause the
activation of PLD (Steinhour et al. 2008). In addition, PLD
isoforms PLD1 and PLD2 have been shown to be regulated
by small GTPases (Oude Weernink 2007). Recently a
novel PLD distantly related to PLD1 and PLD2 at amino
acid sequence level was found to be localized in the
mitochondrial outer membrane and to promote organelle
fusion (Choi et al. 2006), by producing fusogenic lipids.
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Fig. 4 Choline metabolic
pathways. The scheme shows
the structures of individual
choline metabolic intermediates
and the enzymes that take part
in the choline metabolic ﬂux.
Metabolites observed in this
study are highlighted
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123The functional relationships between phospholipases
and mitochondria are complex, but they may be crucial for
understanding speciﬁc mitochondrial dysfunction. Overall,
it appears that the inhibition of ETS complexes promotes
rapid turnover of membrane phospholipids, possibly regu-
lating mitochondrial membrane dynamics that include
fusion and ﬁssion activities. Such changes might reﬂect the
ability of cells to compensate for functional deﬁcits fol-
lowing the inhibition of ETS complexes. Furthermore, the
lipid metabolites produced by activation of phospholipases
following ETS inhibition might also modulate a host of
signal transduction activities, which could contribute to
mitochondrial remodeling and adaptation to ETS
inhibition.
We suggest here that the inhibition of each ETS com-
plex has speciﬁc biochemical consequences that are
reﬂected by unique cellular metabolic proﬁles. These pro-
ﬁles can be used to distinguish the speciﬁc functional
deﬁcits associated with each ETS complex. Our observa-
tion of ETS complex-speciﬁc alterations in Cho metabolic
patterns could offer a new understanding of mitochondrial
dysfunction. Both nuclear and mitochondrial gene muta-
tions as well as environmental factors are known to impair
the function of speciﬁc ETS complexes in animals and
humans; e.g., reduction of Complex I activity has been
observed in PD patients (Schapira et al. 1989). Further
evidence of the involvement of Complex I in PD patho-
genesis comes from the use of MPTP treatment in animal
models, which recapitulated PD-like symptoms (Bove
et al. 2005). Another CNS disease, HD, is known to be
caused by an expansion of the CAG trinucleotide repeats in
the Huntington (Htt) gene. This is manifested by a poly-
glutamine track expansion in the Htt protein. Although Htt
is not a mitochondrial protein, there has been signiﬁcant
mitochondrial dysfunction reported for HD patients. Both
Complexes II and III activities were found to be decreased
by more than half, in addition to a one-third reduction in
Complex IV activity in HD patients (Browne et al. 1997).
3-NP, an inhibitor of Complex II, was able to induce HD-
like pathology in animal brains (Beal et al. 1993). Elevated
tCho has been found in many of the CNS diseases, similar
to our observation in neuroblastoma cells treated with ETS
inhibitors. MRS technology for in vivo imaging, however,
does not yet have the resolution to differentiate Cho from
PC and GPC. Once clinical MRS technology is able to
distinguish various Cho metabolites, it may be interesting
to see whether ETS complex-speciﬁc dysfunction can be
mapped in different CNS diseases. Several key questions
remain: it is unclear how inhibition of different ETS
complexes could selectively affect phospholipases associ-
ated with PtdCho and Cho pathways. Studies in cancer
have already produced clues. Recently cholinekinase was
shown to be induced by HIF-1a in human prostate cancer
cells (Glunde et. al. 2008). Our data has indicated that
similar signal transduction events could be propagated
from pathways triggered by ETS complex inhibition
(Fig. 3). Alternatively, the observed results could be due to
non-speciﬁc off-target inhibition of choline metabolic
enzymes by the ETS complex inhibitors. Each possibility
should be dissected in details for future studies.
5 Concluding remarks
Choline metabolic dysregulation might play an important
role in the manifestation of mitochondrial dysfunction.
Such aberrant Cho metabolic patterns could be useful to
distinguish speciﬁc abnormalities within individual ETS
complex and to understand their downstream phospholi-
pase signal transduction pathways.
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